Ocular Therapeutix
OCUL
57 hedge funds and large institutions have $557M invested in Ocular Therapeutix in 2015 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 2 closing their positions.
1,000% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 2
216% more capital invested
Capital invested by funds: $176M → $557M (+$381M)
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
110% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 10
54% more funds holding
Funds holding: 37 → 57 (+20)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVMCV
Polaris Venture Management Co V
Boston,
Massachusetts
|
+$66.7M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$38.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$35.9M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$26.3M |
| 5 |
LCP
Lamond Capital Partners
San Francisco,
California
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RIM
RS Investment Management
San Francisco,
California
|
-$10.4M |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$6.58M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$4.02M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.4M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
-$2.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Royal Bank of Canada
Toronto,
Ontario, Canada
| $18K | -$10.1K | -308 | -42% |
|
52
Citigroup
New York
| $13K | -$965K | -29,358 | -99% |
|
53
Barclays
London,
United Kingdom
| $7K | -$80.7K | -2,454 | -93% |
|
54
BNP Paribas Financial Markets
Paris,
France
| $5.5K | +$4.31K | +131 | New |
|
|
TDC
55
Thompson Davis & Co
Richmond,
Virginia
| $5K | -$8.22K | -250 | -67% |
|
56
Bank of America
Charlotte,
North Carolina
| $1K | +$756 | +23 | New |
|
57
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $195 | +$100K | +3,045 | +189% |
|
|
SM
58
Sabby Management
Miami Beach,
Florida
| – | -$2.33K | -98,951 | Closed |
|
|
NI
59
Numeric Investors
Boston,
Massachusetts
| – | -$654K | -27,802 | Closed |
|
OCUL Hedge Fund Activity: Q1 2015 in Review
57 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q1 2015, worth a combined $557M — up 216% from $176M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new OCUL positions and 2 closed out — a net gain of 20 holders — while 21 added to existing stakes and 10 trimmed.
The largest buyer was Polaris Venture Management Co V, opening a new position worth an estimated $66.7M. The largest seller was RS Investment Management, cutting an estimated $10.4M.
- 57 institutional investors held Ocular Therapeutix (OCUL) as of Q1 2015, up from 37 in Q4 2014.
- Funds reported $557M of Ocular Therapeutix stock for Q1 2015, up 216% quarter-over-quarter.
- 22 funds opened new Ocular Therapeutix positions in Q1 2015 and 2 closed out, a net change of +20 holders.
- The largest Ocular Therapeutix buyer in Q1 2015 was Polaris Venture Management Co V, an estimated $66.7M added.
- The largest Ocular Therapeutix seller in Q1 2015 was RS Investment Management, an estimated $10.4M sold.
Based on aggregated 13F filings for Q1 2015.